Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Therapeutics shares soar on FDA panel's support for muscular dystrophy therapeutic
11:03am, Monday, 15'th May 2023
Sarepta Therapeutics shares added almost 25% on Monday morning after the US Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee voted eight to six in favor of the
Why Sarepta Therapeutics Stock Is Skyrocketing Today
10:59am, Monday, 15'th May 2023
An FDA advisory committee voted 8-6 in favor of accelerated approval for SRP-9001. The FDA doesn't have to go along with the advisory committee's recommendation, but usually does.
2 Supercharged Growth Stocks to Buy Right Now
04:00pm, Sunday, 14'th May 2023
Growth stocks have been top-performers during the first five months of 2023. This broad-based rally is in danger of stalling because of numerous storm clouds on the horizon.
FDA advisers narrowly back accelerated approval of Sarepta gene therapy
07:13pm, Friday, 12'th May 2023
U.S. Food and Drug Administration advisers voted 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.'s gene therapy for Duchenne muscular dystrophy despite quest
Sarepta Therapeutics stock halted premarket ahead of FDA panel meeting on new Duchenne muscular dystrophy treatment
07:44am, Friday, 12'th May 2023
Sarepta Therapeutics Inc. stock SRPT, -0.88% was halted premarket Friday, ahead of a meeting of a Food and Drug Administration advisory panel to discuss the company's SRP-9001 gene therapy for the rar
Why Sarepta Therapeutics Stock Faded This Week
02:23pm, Thursday, 11'th May 2023
Sarepta Therapeutics is heading into an important expert panel review this Friday for its Duchenne muscular dystrophy gene therapy candidate. The FDA's briefing documents ahead of this meeting raised
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
12:55pm, Wednesday, 03'rd May 2023
Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.
Sarepta Therapeutics, Inc. (SRPT) Q1 2023 Earnings Call Transcript
08:52pm, Tuesday, 02'nd May 2023
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Mary Jenkins – Associate Director-Investor Relations Doug Ingram – President
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
07:09pm, Tuesday, 02'nd May 2023
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to loss of $1.20 per share a year ago.
These Are the Top 10 Holdings of Avoro Capital Advisors
10:54pm, Monday, 17'th Apr 2023
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy
01:42pm, Friday, 14'th Apr 2023
Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.
Sarepta shares tumble as concerns mount over FDA approval on gene therapy
03:44pm, Thursday, 13'th Apr 2023
CNBC's Meg Tirrell joins 'Power Lunch' to discuss the Sarepta's gene therapy for muscular dystrophy, and why the stock is taking a tumble over doubts around Sarepta receiving FDA approval.
Sarepta Therapeutics Tumbles on Gene Therapy Drama
11:03am, Thursday, 13'th Apr 2023
A report raised questions about the chances for approval of the company's gene therapy to treat Duchenne muscular dystrophy.
Sarepta Therapeutics shares fall as report says FDA almost rejected its gene therapy
10:26am, Thursday, 13'th Apr 2023
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares took a beating Thursday as Stat News reported that reviewers at the US Food and Drug Administration (FDA) were leaning toward rejecting a closely watched
Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy
10:11am, Thursday, 13'th Apr 2023
Several FDA staffers were leaning toward rejecting a highly watched gene therapy from Sareptas, according to a report Thursday that sent SRPT stock into a dive. The post Sarepta Tumbles As Report Of I
